RT Journal Article
SR Electronic
T1 Pneumocystis jirovecii pneumonia in a patient treated with trastuzumab-deruxtecan
JF BMJ Case Reports
JO BMJ Case Reports
FD BMJ Publishing Group Ltd
SP e253647
DO 10.1136/bcr-2022-253647
VO 16
IS 2
A1 Haneen Mallah
A1 Ellery Altshuler
A1 Brian Ramnaraign
A1 Ali Khawaja
YR 2023
UL http://casereports.bmj.com/content/16/2/e253647.abstract
AB Trastuzumab-deruxtecan (T-DXd) is a novel antibody drug conjugate that has improved treatment outcomes in patients with ERBB2-positive cancer, including locally advanced or metastatic gastric and gastro-oesophageal junction adenocarcinoma. One of the reported side effects of this medication is drug-induced pneumonitis. We present in this case report, a diagnostic dilemma of a patient presenting with clinical and radiographical features of drug-induced pneumonitis but was found to have pneumocystis jirovecii pneumonia (PJP). Our case is the first of PJP in a patient treated with T-DXd, highlighting the increasing incidence of this opportunistic infection in patients with solid malignancy. It also highlights the clinical and radiographical similarities between the PJP and drug-induced pneumonitis.